Loading…
Reported covered position: Congressman John Tierney Senator Tom Carper
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2025 · first_quarter · Q1
Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launch
Section 232 investigation into pharmaceuticals and unfair trade practices
Source: Senate LDA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Elijah E. Cummings Lower Drug Costs Now Act
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Client: FRESENIUS KABI USA LLC · Firm: FRESENIUS KABI USA LLC
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Sec. 232 investigation on pharmaceutical sector, tariffs, made in America
PBM reform, including spread pricing, AWP policy, ASP policy
PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty
BEAT, AMT, U.S. manufacturing incentives
Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2024 · fourth_quarter · Q4
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
PBM reform, IRA Medicare Direct Negotiation, FDA/PTO
Tax incentives for American production of pharmaceutical product, opioid taxes
Patent Reform, terminal disclaimers, ancillary product patents
Buy America legislation, potential manufacturing tariffs, tax reform on fill and finish pharmaceutical products
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes, patent reform, terminal disclaimers, ancillary product patents
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2024 · third_quarter · Q3
Tax incentives for American production of pharmaceutical product, opioid taxes
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes, patent reform, terminal disclaimers, ancillary product patents
Rebate reform, any willing pharmacy, PBM reform, IRA Medicare Direct Negotiation, DIR fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2024 · second_quarter · 2A
Tax incentives for American production of pharmaceutical product, opioid taxes
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Rebate reform, any willing pharmacy, PBM reform, IRA Medicare Direct Negotiation, DIR fees
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes, patent reform, terminal disclaimers, ancillary product patents
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2024 · second_quarter · Q2
Tax incentives for American production of pharmaceutical product, opioid taxes
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Rebate reform, any willing pharmacy, PBM reform, IRA Medicare Direct Negotiation, DIR fees
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes, patent reform, terminal disclaimers, ancillary product patents
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2024 · first_quarter · Q1
Tax incentives for American production of pharmaceutical product, opioid taxes
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2023 · fourth_quarter · Q4
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2023 · third_quarter · Q3
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees
Tax incentives for American production of pharmaceutical product, opioid taxes
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2023 · second_quarter · Q2
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Tax incentives for American production of pharmaceutical product, opioid taxes
Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2023 · first_quarter · Q1
Tax incentives for American production of pharmaceutical product, opioid taxes
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
Rebate reform, any willing pharmacy
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2022 · fourth_quarter · Q4
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation, FDA User Fee legislation
Buy America, supply chain integrity
Tax Reform, Section 199, BEAT, Gilty, Buy America, Patent Reform
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2022 · third_quarter · Q3
Buy America, supply chain integrity
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation, FDA User Fee legislation
Tax Reform, Section 199, BEAT, Gilty, Buy America, Patent Reform
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2022 · second_quarter · Q2
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation, FDA User Fee legislation
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Buy America, supply chain integrity
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2022 · first_quarter · Q1
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation, FDA User Fee legislation
Buy America, supply chain integrity
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2021 · fourth_quarter · Q4
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation
Tax Reform, Section 199, BEAT, Gilty, Buy America, Patent Reform
Buy America, supply chain integrity
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2021 · third_quarter · Q3
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog, Reconciliation
Tax Reform, Section 199, BEAT, Gilty, Buy America
Buy America, supply chain integrity
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2021 · second_quarter · Q2
Tax Reform, Section 199, BEAT, Gilty, Buy America
Buy America, supply chain integrity
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2021 · first_quarter · Q1
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog
Tax Reform, Section 199, BEAT, Gilty, Buy America
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2020 · fourth_quarter · Q4
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2020 · third_quarter · Q3
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
FRESENIUS KABI USA LLC via FRESENIUS KABI USA LLC
2020 · third_quarter · RA
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Tax incentives for American production of pharmaceutical product, opioid taxes
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
IRA, Part D redesign, rebates, AMP CAP, inflationary penalties, mid-year formulary changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Tax Reform, Section 199, BEAT, Gilty, Buy America, Patent Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Tax Reform, Section 199, BEAT, Gilty, Buy America, Patent Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, White House Office
Rebate Reform, Medicare Part D Redesign, Inflationary penalties, Drug pricing legislation, International reference pricing, Medicare direct negotiations, reconciliation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Drug pricing legislation, Biosimilars, Patent Reform, Rebate Reform, BLOCKING Act, Electronic Labeling, FDA Foreign Inspection backlog
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Buy America
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BLOCKING Act, Medical device tax, opioids, intellectual property, data exclusivity, CURES, Medicare Part A, B, C, D, Medicaid rebates and inflationary penalties, HR3, Biosimilars, generic medicines, S1391, PDPRA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.